New prospects for the management of renal bone disease

Nephron - Clinical Practice

Volumn 99, Issue 1, 2005, Pages

  Steddon, Simon J ^a   Fan, Stanley L S ^a   Cunningham, John ^b,c  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Adynamic bone disease; Bone remodelling; Calcium; Osteodystrophy; Phosphorus; Vitamin D

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCITRIOL; CINACALCET; COLECALCIFEROL; CYTOKINE; ERGOCALCIFEROL; LANTHANUM CARBONATE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

BIOLOGY; BONE DEVELOPMENT; BONE DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CYTOKINE PRODUCTION; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MICROENVIRONMENT; NEPHROLOGY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY; SURVIVAL; TOXICITY; VITAMIN D DEFICIENCY;

ANIMALS; BONE REMODELING; CALCIUM; CARRIER PROTEINS; HUMANS; HYPERPARATHYROIDISM; HYPERPLASIA; MEMBRANE GLYCOPROTEINS; NAPHTHALENES; OSTEOCLASTS; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROIDECTOMY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 12444290841     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081787     Document Type: Short Survey

References (27)

1. Urena P, De Vernejoul MC: Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999;55:2141-2156.
2. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753-761.
3. Goodman WG, Juppner H, Salusky IB, Sherrard DJ: Parathyroid hormone (PTH), PTHderived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 2003;63:1-11.
4. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J: Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43:566-571.
5. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
6. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-615.
7. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveirados-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
8. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360.
9. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100:2977-2983.
10. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1-201.
11. Cannata-Andia J, Fernandez-Martin JL, Diaz-Corte C: Applying the K/DOQI guidelines cut off levels to the dialysis population: How far are we from the target? J Am Soc Nephrol 2003;14(suppl 11):474A.
12. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-1024.
13. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-583.
14. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-1525.
15. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
16. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
17. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcifi cation. Circ Res 2000;87:E10-E17.
18. Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, Langos V, Uldall R: Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol 1998;9:859-868.
19. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcifi cation in hemodialysis patients. Kidney Int 2002;62:245-252.
20. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-1926.
21. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E: The effects of sevelamer hydrochloride and calcium carbonate on kidney calcifi cation in uremic rats. J Am Soc Nephrol 2002;13:2299-2308.
22. McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J: Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease. Kidney Int 1999;55:500-511.
23. Monier-Faugère MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH: 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999;55:821-832.
24. Chen NX, O'Neill KD, Duan D, Moe SM: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-1731.
25. Davies MR, Lund RJ, Hruska KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003;14:1559-1567.
26. Gonzalez EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM, Sampath TK, Hruska KA: Treatment of a murine model of highturnover renal osteodystrophy by exogenous BMP-7. Kidney Int 2002;61:1322-1331.
27. Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcifi cation induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001;21:1610-1616.